Free Trial
NASDAQ:CGTX

Cognition Therapeutics Q2 2025 Earnings Report

Cognition Therapeutics logo
$2.43 0.00 (0.00%)
Closing price 09/2/2025 04:00 PM Eastern
Extended Trading
$2.46 +0.03 (+1.23%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Cognition Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cognition Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Cognition Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cognition Therapeutics Earnings Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dollar portfolio today… Back then… one financial expert begged people to look at Nvidia -- when it was trading at just $1.10! Now… he’s urging you to look at a new group of seven stocks…tc pixel
See More Cognition Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email.

About Cognition Therapeutics

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

View Cognition Therapeutics Profile

More Earnings Resources from MarketBeat